Advanced aerosol delivery devices for potential cure of acute and chronic diseases

Critical Reviews in Therapeutic Drug Carrier Systems

Volumn 31, Issue 6, 2014, Pages 495-530

  Kaur, Ranjot ^a   Garg, Tarun ^a   Rath, Goutam ^a   Goyal, Amit K ^a  

^a ISF COLLEGE OF PHARMACY   (India)

Author keywords

Aerosol delivery devices; Dry powder inhalers; Metered dose inhalers; Nebulizers

Indexed keywords

ALENDRONIC ACID; AMIKACIN; AMILORIDE; ATROPINE; BECLOMETASONE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CROMOGLYCATE DISODIUM; DAPSONE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FLUTICASONE; FORMOTEROL; GLUCAGON; HEPARIN; IMMUNOGLOBULIN G; INSULIN; LEUCINE; LEVOFLOXACIN; MOMETASONE FUROATE; MOXIFLOXACIN; OFLOXACIN; RIFAMPICIN; SALBUTAMOL; SALBUTAMOL SULFATE; TACROLIMUS; TEMOZOLOMIDE; UNINDEXED DRUG;

ACUTE RESPIRATORY TRACT DISEASE; ARTICLE; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CHRONIC RESPIRATORY TRACT DISEASE; DEVICE COMPARISON; DRY POWDER INHALER; EQUIPMENT DESIGN; HUMAN; INHALATION SPACER; INHALER; METERED DOSE INHALER; NEBULIZER; PRECIPITATION; SPRAY DRYING; VELOCITY; ACUTE DISEASE; CHRONIC DISEASE; DRUG DELIVERY SYSTEM; INHALATIONAL DRUG ADMINISTRATION;

ACUTE DISEASE; ADMINISTRATION, INHALATION; CHRONIC DISEASE; DRUG DELIVERY SYSTEMS; HUMANS;

EID: 84907292777     PISSN: 07434863     EISSN: 2162660X     Source Type: Journal    
DOI: 10.1615/CritRevTherDrugCarrierSyst.2014010527     Document Type: Article

References (203)

1. Karhale Ashish ACHS, Ughade Prajkta L, Baviskar Dheeraj T, Jain Dinesh K. Pulmonary drug delivery system. Int J PharmTech Res. 2012; 4(1):293-305.
2. Shaikh SNS, Khan T, Shaikh A, Zameeruddin M, Quazi A. Recent advances in pulmonary drug delivery system: a review. Int J Appl Pharm. 2010;2(4):0975-7058.
3. Sung JC, Pulliam BL, Edwards DA. Nanoparticles for drug delivery to the lungs. Trends Biotechnol. 2007;25(12):563-70.
4. Sunitha R. Drug delivery and its developments for pulmonary system. Int J Pharm Chem Biol Sci. 2011;1(1):66-82.
5. Garg T, Goyal AK. Biomaterial-based scaffolds—current status and future directions. Expert Opin Drug Deliv. 2014.
6. Touw DJ, Brimicombe RW, Hodson ME, Heijerman HG, Bakker W. Inhalation of antibiotics in cystic fibrosis. Eur Respir J. 1995;8(9):1594-604.
7. Tran NP, Vickery J, Blaisis MS. Management of rhinitis: allergic and non-allergic. Allergy Asthma Immunol Res. 2011;3(3):148-56.
8. Muchão FP, Silva Filho LVRF. Avanços na inaloterapia em pediatria. Jornal de Pediatria. 2010;86:3 67-76.
9. Garg T, Rath G, Goyal AK. Comprehensive review on additives of topical dosage forms for drug delivery. Drug Deliv. 2014.
10. Byron PR. Prediction of drug residence times in regions of the human respiratory tract following aerosol inhalation. J Pharm Sci. 1986;75(5):433-8.
11. Newman S., Clarke S.W. Therapeutic aerosols 1—physical and practical considerations. Thorax. 1983;38(12):881-6.
12. Bisgaard H. Drug delivery from inhaler devices. Br Med J. 1996;313:895-6.
13. Tobyn M, Staniforth JN, Morton D, Harmer Q, Newton ME. Active and intelligent inhaler device development. Int J Pharm. 2004;277(1-2):31-7.
14. Robert O, Williams I, David R. Advanced drug formulation design to optimize therapeutic outcomes. Informa Healthcare USA Inc, New York,. 2008;172:1-50.
15. Johnson MA, Newman S., Bloom R, Talaee N, Clarke SW. Delivery of albuterol and ipratropium bromide from two nebulizer systems in chronic stable asthma. Chest. 1989;96(1):6-10.
16. Zanen PGLT, Lammers JWJ. Optimal particle size of β2 agonist and anticholinergic aerosols in patients with severe airflow obstruction. Thorax. 1996:977-80.
17. Donovan MJ, Smyth HD. Influence of size and surface roughness of large lactose carrier particles in dry powder inhaler formulations. Int J Pharm. 2010;402(1-2):1-9.
18. Freedman T. Medihaler therapy for bronchial asthma; a new type of aerosol therapy. Postgrad Med. 1956;20(6):667-73.
19. Bell JH, Hartley PS, Cox JS. Dry powder aerosols. I. A new powder inhalation device. J Pharm Sci. 1971;60(10):1559-64.
20. Altounyan REC. Inhibition of experimental asthma by a new compoundsodium cromoglycate. Intal Acta Allergol 1967;22:487-9.
21. Basheti IA, Reddel HK, Armour CL, Bosnic-Anticevich SZ. Improved asthma outcomes with a simple inhaler technique intervention by community pharmacists. J Allergy Clin Immunol. 2007;119(6): 1537-8.
22. Cain WT, Cable G, Oppenheimer JJ. The ability of the community pharmacist to learn the proper actuation techniques of inhaler devices. J Allergy Clin Immunol. 2001;108(6):918-20.
23. Kelling JS, Strohl KP, Smith RL, Altose MD. Physician knowledge in the use of canister nebulizers. Chest. 1983;83(4):612-4.
24. Hanania NA, Wittman R, Kesten S, Chapman KR. Metered-dose inhalers, spacing chambers, and breath-actuated dry powder inhalers. Chest. 1994;105(1):111-6.
25. Jones JS, Holstege CP, Riekse R, White L, Bergquist T. Metered-dose inhalers: do emergency health care providers know what to teach? Ann Emerg Med. 1995;26(3):308-11.
26. Jackevicius CA, Chapman KR. Inhaler education for hospital-based pharmacists: how much is required? Can Respir J. 1999;6(3):237-44.
27. Basheti IA, Reddel HK, Armour CL, Bosnic-Anticevich SZ. Counseling about turbuhaler technique: needs assessment and effective strategies for community pharmacists. Respir Care. 2005;50(5): 617-23.
28. Singh H, Sharma R, Joshi M, Garg T, Goyal AK, Rath G. Transmucosal delivery of Docetaxel by mucoadhesive polymeric nanofibers. Artif Cells Nanomed Biotechnol. 2014.
29. Kaur M, Malik B, Garg T, Rath G, Goyal AK. Development and characterization of guar gum nanoparticles for oral immunization against tuberculosis. Drug Deliv. 2014.
30. Garg T, Singh S, Goyal AK. Stimuli-sensitive hydrogels: an excellent carrier for drug and cell delivery. Crit Rev Ther Drug Carrier Syst. 2013;30(5):369-409.
31. Parnami N, Garg T, Rath G, Goyal AK. Development and characterization of nanocarriers for topical treatment of psoriasis by using combination therapy. Artif Cells Nanomed Biotechnol. 2013.
32. Garg T, Goyal AK. Iontophoresis: drug delivery system by applying an electrical potential across the skin. Drug delivery letters. 2012;2(4):270-80.
33. Garg T. An evolutionary approaches in development of needle free injection technologies. Int J Pharm Pharmaceut Sci. 2012;4(1):590-6.
34. Franklin W, Lowell FC, Michelson AL, Schiller IW. Aerosolized steroids in bronchial asthma. J Allergy. 1958;29(3):214-21.
35. Bloomfield P, Crompton GK, Winsey NJ. A tube spacer to improve inhalation of drugs from pressurised aerosols. Br Med J. 1979;2(6203):1479.
36. Smith IJ, Parry-Billings M. The inhalers of the future? A review of dry powder devices on the market today. Pulm Pharmacol Ther. 2003;16(2):79-95.
37. Srichana T, Martin GP, Marriott C. Dry powder inhalers: the influence of device resistance and powder formulation on drug and lactose deposition in vitro. Eur J Pharm Sci. 1998;7(1):73-80.
38. Crompton GK. Dry powder inhalers: advantages and limitations. J Aerosol Med. 1991;4(3):151-6.
39. Zeng XM, Martin GP, Tee SK, Ghoush AA, Marriott C. Effects of particle size and adding sequence of fine lactose on the deposition of salbutamol sulphate from a dry powder formulation. Int J Pharm. 1999;182(2):133-44.
40. Louey M, Stewart P. Particle interactions involved in aerosol dispersion of ternary interactive mixtures. Pharmaceutical Research. 2002;19(10):1524-31.
41. Islam N, Gladki E. Dry powder inhalers (DPIs)—a review of device reliability and innovation. Int J Pharm. 2008;360(1-2):1-11.
42. Atkins PJ. Dry powder inhalers: an overview. Respir Care. 2005;50(10):1304-12.
43. Hess DR. Metered-dose inhalers and dry powder inhalers in aerosol therapy. Respir Care. 2005;50(10):1376-83.
44. Chan HK. Dry powder aerosol delivery systems: current and future research directions. J Aerosol Med. 2006;19(1):21-7.
45. Dunbar C. Dry powder formulations for inhalation. Drug Deliv Syst Sci. 2002;2:78-80.
46. Kelly HW. Innovations in dry powder inhalation systems, in dry powder inhalers in the treatment of asthma: a continuing education monograph for physicians, nurses, pharmacists, physician assistants and respiratory therapists. Meniscus, USA. 2002:10-8.
47. Ashurst II, Malton A, Prime D, Sumby B. Latest advances in the development of dry powder inhalers. Pharm Sci Technolo Today. 2000;3(7):246-56.
48. Newman SP. Dry powder inhalers for optimal drug delivery. Expert Opin Biol Ther. 2004;4(1): 23-33.
49. Telko MJ, Hickey AJ. Dry powder inhaler formulation. Respir Care. 2005;50(9):1209-27.
50. Newman S., Busse WW. Evolution of dry powder inhaler design, formulation, and performance. Respir Med. 2002;96(5):293-304.
51. Clark AR. Medical aerosol inhalers: past, present, and future. Aerosol Sci Technol. 1995;22:374-91.
52. Ahrens R, Lux C, Bahl T, Han SH. Choosing the metered-dose inhaler spacer or holding chamber that matches the patient’s need: Evidence that the specific drug being delivered is an important consideration. J Allergy Clin Immunol. 1995;96(2, Supplement):288-94.
53. Zeng XM, Jones S, O’Leary D, Phelan M, Colledge J. Delivery of formoterol from a novel multi-dose inhaler Airmax. Respir Med. 2002;96(6):397-403.
54. Crowder TM, Louey, MD, Sethuraman, VV, Smyth HDC., Hickey AJ. An odyssey in inhaler formulations and design. Pharm Technol. 2001;25:99-113.
55. Mahadewsingh JV, Hamersma WB, Schreurs AJ. Relative efficacy of three different inhalers containing salbutamol in patients with asthma. Eur J Clin Pharmacol. 1996;50(6):467-9.
56. Young PM, Thompson J, Woodcock D, Aydin M, Price R. The development of a novel high-dose pressurized aerosol dry-powder device (PADD) for the delivery of pumactant for inhalation therapy. J Aerosol Med. 2004;17(2):123-8.
57. Brown BASRJ, Becker DP, Friend DR. A piezo-electronic inhaler for local & systemic applications. Drug Deliv Technol 2004;4:90-3.
58. Kaur M, Garg T, Rath G, Goyal AK. Current nanotechnological strategies for effective delivery of bioactive drug molecules in the treatment of tuberculosis. Crit Rev Ther Drug Carrier Syst. 2014;31(1):49-88.
59. Garg T, Goyal AK, Malik B, Arora S, Murthy R. Development, optimization & evaluation of porous chitosan scaffold formulation of gliclazide for the treatment of type-2 diabetes mellitus. Drug delivery letters. 2012;2(4):251-61.
60. Garg T, Chanana A. Dry powder inhalers- recent trends. Indo-global Res J Pharmaceut Sci. 2012;2(4):443-9.
61. de Boer AH, Le Brun PP, van der Woude HG, Hagedoorn P, Heijerman HG, Frijlink HW. Dry powder inhalation of antibiotics in cystic fibrosis therapy, part 1: development of a powder formulation with colistin sulfate for a special test inhaler with an air classifier as de-agglomeration principle. Eur J Pharm Biopharm. 2002;54(1):17-24.
62. Newman S., Pitcairn GR, Hirst PH, Bacon RE, O’Keefe E, Reiners M. Scintigraphic comparison of budesonide deposition from two dry powder inhalers. Eur Respir J. 2000;16(1):178-83.
63. Harper NJ, Gray S, De Groot J, Parker JM, Sadrzadeh N, Schuler C. The design and performance of the exubera pulmonary insulin delivery system. Diabetes Technol Ther. 2007;9 Suppl 1:S16-27.
64. Nelson H, Kemp JP, Bieler S, Vaughan LM, Hill MR. Comparative efficacy and safety of albuterol sulfate Spiros inhaler and albuterol metered-dose inhaler in asthma. Chest. 1999;115(2):329-35.
65. Warren STG, Godfrey C, Cote G, Hill M. Gamma scintigraphic evaluation of dry powder beclomethasone dipropionate (BDP) from an investigational spiros® inhaler: Effect of inspiratory flow profile on pulmonary drug deposition. Am J Respir Crit Care Med 1999;159:A118.
66. Agertoft L, Pedersen S. Effects of long-term treatment with an inhaled corticosteroid on growth and pulmonary function in asthmatic children. Respir Med. 1994;88(5):373-81.
67. Zhang X, Ma Y, Zhang L, Zhu J, Jin F. The development of a novel dry powder inhaler. Int J Pharm. 2012;431(1-2):45-52.
68. Varshosaz J, Hassanzadeh F, Mardani A, Rostami M. Feasibility of haloperidol-anchored albumin nanoparticles loaded with doxorubicin as dry powder inhaler for pulmonary delivery. Pharm Dev Technol. 2013.
69. Duan J, Vogt FG, Li X, Hayes D, Jr., Mansour HM. Design, characterization, and aerosolization of organic solution advanced spray-dried moxifloxacin and ofloxacin dipalmitoylphosphatidylcholine (DPPC) microparticulate/nanoparticulate powders for pulmonary inhalation aerosol delivery. Int J Nanomedicine. 2013;8:3489-505.
70. Wu X, Hayes D, Zwischenberger JB, Kuhn RJ, Mansour HM. Design and physicochemical characterization of advanced spray-dried tacrolimus multifunctional particles for inhalation. Drug Des Devel Ther. 2013;7:59-72.
71. El-Gendy N, Selvam P, Soni P, Berkland C. Development of budesonide nanocluster dry powder aerosols: preformulation. J Pharm Sci. 2012;101(9):3434-44.
72. Sultana S, Talegaonkar S, Ali R, Mittal G, Ahmad FJ, Bhatnagar A. Inhalation of alendronate nanoparticles as dry powder inhaler for the treatment of osteoporosis. J Microencapsul. 2012;29(5): 445-54.
73. Wang Y, Kho K, Cheow WS, Hadinoto K. A comparison between spray drying and spray freeze drying for dry powder inhaler formulation of drug-loaded lipid-polymer hybrid nanoparticles. Int J Pharm. 2012;424(1-2):98-106.
74. Klingler C, Muller BW, Steckel H. Insulin micro and nanoparticles for pulmonary delivery. Int J Pharm. 2009;377(1-2):173-9.
75. Kaye RS, Purewal TS, Alpar HO. Simultaneously manufactured nano-in-micro (SIMANIM) particles for dry-powder modified-release delivery of antibodies. J Pharm Sci. 2009;98(11):4055-68.
76. Ali R, Jain GK, Iqbal Z, Talegaonkar S, Pandit P, Sule S. Development and clinical trial of nanoatropine sulfate dry powder inhaler as a novel organophosphorous poisoning antidote. Nanomedicine. 2009;5(1):55-63.
77. Surti N, Naik S, Bagchi T, Dwarkanath BS, Misra A. Intracellular delivery of nanoparticles of an antiasthmatic drug. AAPS PharmSciTech. 2008;9(1):217-23.
78. Jinturkar KA, Anish C, Kumar MK, Bagchi T, Panda AK, Misra AR. Liposomal formulations of Etoposide and Docetaxel for p53 mediated enhanced cytotoxicity in lung cancer cell lines. Biomaterials. 2012;33(8):2492-507.
79. Huang WH, Yang ZJ, Wu H, Wong YF, Zhao ZZ, Liu L. Development of liposomal salbutamol sulfate dry powder inhaler formulation. Biol Pharm Bull. 2010;33(3):512-7.
80. Chougule M, Padhi B, Misra A. Development of spray dried liposomal dry powder inhaler of Dapsone. AAPS PharmSciTech. 2008;9(1):47-53.
81. Chougule MB, Padhi BK, Misra A. Nano-liposomal dry powder inhaler of amiloride hydrochloride. J Nanosci Nanotechnol. 2006;6(9-10):3001-9.
82. Shah SP, Misra A. Liposomal amikacin dry powder inhaler: effect of fines on in vitro performance. AAPS PharmSciTech. 2004;5(4):e65.
83. Waldrep JC, Gilbert BE, Knight CM, Black MB, Scherer PW, Knight V. Pulmonary delivery of beclomethasone liposome aerosol in volunteers. Tolerance and safety. Chest. 1997;111(2):316-23.
84. Tuli RA, George GA, Dargaville TR, Islam N. Studies on the effect of the size of polycaprolactone microspheres for the dispersion of salbutamol sulfate from dry powder inhaler formulations. Pharm Res. 2012;29(9):2445-55.
85. Puapermpoonsiri U, Spencer J, van der Walle CF. A freeze-dried formulation of bacteriophage encapsulated in biodegradable microspheres. Eur J Pharm Biopharm. 2009;72(1):26-33.
86. Onoue S, Kuriyama K, Uchida A, Mizumoto T, Yamada S. Inhalable sustained-release formulation of glucagon: in vitro amyloidogenic and inhalation properties, and in vivo absorption and bioactivity. Pharm Res. 2011;28(5):1157-66.
87. Ungaro F, d’Emmanuele di Villa Bianca R, Giovino C, Miro A, Sorrentino R, Quaglia F. Insulinloaded PLGA/cyclodextrin large porous particles with improved aerosolization properties: in vivo deposition and hypoglycaemic activity after delivery to rat lungs. J Control Release. 2009;135(1):25-34.
88. Wauthoz N, Deleuze P, Saumet A, Duret C, Kiss R, Amighi K. Temozolomide-based dry powder formulations for lung tumor-related inhalation treatment. Pharm Res. 2011;28(4):762-75.
89. Shur J, Nevell TG, Ewen RJ, Price R, Smith A, Barbu E. Cospray-dried unfractionated heparin with Lleucine as a dry powder inhaler mucolytic for cystic fibrosis therapy. J Pharm Sci. 2008;97(11):4857-68.
90. Maretti E, Rossi T, Bondi M, Croce MA, Hanuskova M, Leo E. Inhaled solid lipid micro-particles to target alveolar macrophages for tuberculosis. Int J Pharm. 2013;462(1-2):74-82.
91. Nolan LM, Li J, Tajber L, Corrigan OI, Healy AM. Particle engineering of materials for oral inhalation by dry powder inhalers. II-Sodium cromoglicate. Int J Pharm. 2011;405(1-2):36-46.
92. Lotvall J, Bleecker ER, Busse WW, O’Byrne PM, Woodcock A, Kerwin EM. Efficacy and safety of fluticasone furoate 100 mug once-daily in patients with persistent asthma: A 24-week placebo and active-controlled randomised trial. Respir Med. 2014;108(1):41-9.
93. Thiel CG. How can we describe the respirability of pharmaceutical aerosols? J Aerosol Med 1997;10(3):2-4.
94. Brown BAS. Dispelling the myths of MDIs. Drug Delivery Technology 2002;2(7):1-7.
95. Dolovich M. New delivery systems and propellants. Can Respir J. 1999;6(3):290-5.
96. Hendeles L, Colice GL, Meyer RJ. Withdrawal of albuterol inhalers containing chlorofluorocarbon propellants. N Engl J Med. 2007;356(13):1344-51.
97. Hardy JG, Jasuja AK, Frier M, Perkins AC. A small volume spacer for use with a breath-operated pressurised metered dose inhaler. Int J Pharmaceut. 1996;142(1):129-33.
98. Noakes T. Medical aerosol propellants. J Fluor Chem. 2002;118(1-2):35-45.
99. Newman SP. Principles of metered-dose inhaler design. Respir Care. 2005;50(9):1177-90.
100. O’Callaghan CWP. The metered-dose inhaler. Allergy Asthma Proc. 2002:3;37-70.
101. Molina MJRF. Stratospheric sink for chlorofluoromethanes: chlorine atom-catalysed destruction of ozone. Nature 1974;249:1810-2.
102. Garg T, Rath G, Goyal AK. Current nanotechnological strategies for an effective delivery of drugs in treatment of periodontal disease. Crit Rev Ther Drug Carrier Syst. 2014;31(2):89-119.
103. Ramteke KHGSS, Sharma YP. Formulation and quality control of metered dose inhalers: a review. Journal of pharmaceutical and scientific innovation. 2012;1(2):44-9.
104. Topliss PWD, Southall J, Purewall T. Pharmaceutical performance of a valve for metered dose inhalers designed to eliminate loss of prime. Respiratory Drug Delivery. 2006:499-502.
105. Wasserman RL, Sheth K, Lincourt WR, Locantore NW, Rosenzweig JC, Crim C. Real-world assessment of a metered-dose inhaler with integrated dose counter. Allergy Asthma Proc. 2006;27(6):486-92.
106. Muchao H. A review of the design and the development of GSK’s MDI dose counter. The Aerosol Society, Portishead. 2005:77-80.
107. Lenney J, Innes JA, Crompton GK. Inappropriate inhaler use: assessment of use and patient preference of seven inhalation devices. Respir Med. 2000;94(5):496-500.
108. Crompton GK. Breath-activated aerosol. Br Med J. 1971;2(5762):652-3.
109. Dalby RZL, Somaraju S, Tsoukleris M, Teeter J. The effect of time delays between inhaler actuation and onset of inhalation on the dose of albuterol exiting Optihaler, Aerochamber and Aerosol Cloud Enhancer spacers. Respiratory Drug Delivery 1996;5:324-6.
110. Newman S., Weisz AW, Talaee N, Clarke SW. Improvement of drug delivery with a breath actuated pressurised aerosol for patients with poor inhaler technique. Thorax. 1991;46(10):712-6.
111. Bell J, Newman S. The rejuvenated pressurised metered dose inhaler. Expert Opin Drug Deliv. 2007;4(3):215-34.
112. Siegfried Wieshammer JD. Dry powder inhalers: factors associated with device misuse. RDD Europe 2009;1:95-104.
113. Hess D, Fisher D, Williams P, Pooler S, Kacmarek RM. Medication nebulizer performance. Effects of diluent volume, nebulizer flow, and nebulizer brand. Chest. 1996;110(2):498-505.
114. Nelson HS, Loffert DT. Comparison of the bronchodilator response to albuterol administered by the OptiHaler, the AeroChamber, or by metered dose inhaler alone. Ann Allergy. 1994;72(4):337-40.
115. Gunawardena KA, Sohal T, Jones JI, Upchurch FC, Crompton GK. The Spacehaler for delivery of salbutamol: a comparison with the standard metered-dose inhaler plus Volumatic spacer device. Respir Med. 1997;91(5):311-6.
116. Kwok PCL, Collins R, Chan HK. Effect of spacers on the electrostatic charge properties of metered dose inhaler aerosols. J Aerosol Sci. 2006;37(12):1671-82.
117. Barry PW, O’Callaghan C. Multiple actuations of salbutamol MDI into a spacer device reduce the amount of drug recovered in the respirable range. Eur Respir J. 1994;7(9):1707-9.
118. Wildhaber JH, Devadason SG, Hayden MJ, James R, Dufty AP, Fox RA. Electrostatic charge on a plastic spacer device influences the delivery of salbutamol. Eur Respir J. 1996;9(9):1943-6.
119. Pierart F, Wildhaber JH, Vrancken I, Devadason SG, Le Souef PN. Washing plastic spacers in household detergent reduces electrostatic charge and greatly improves delivery. Eur Respir J. 1999;13(3):673-8.
120. Kenyon CJ, Thorsson L, Borgstrom L, Newman SP. The effects of static charge in spacer devices on glucocorticosteroid aerosol deposition in asthmatic patients. Eur Respir J. 1998;11(3):606-10.
121. Morén F. Drug deposition of pressurized inhalation aerosols I. Influence of actuator tube design. Int J Pharmaceut. 1978;1(4):205-12.
122. El-Gendy N, Gorman EM, Munson EJ, Berkland C. Budesonide nanoparticle agglomerates as dry powder aerosols with rapid dissolution. J Pharm Sci. 2009;98(8):2731-46.
123. Hindle M, Longest PW. Condensational growth of combination drug-excipient submicrometer particles for targeted high-efficiency pulmonary delivery: evaluation of formulation and delivery device. J Pharm Pharmacol. 2012;64(9):1254-63.
124. Tan Y, Yang Z, Pan X, Chen M, Feng M, Wang L. Stability and aerosolization of pressurized metered dose inhalers containing thymopentin nanoparticles produced using a bottom-up process. Int J Pharm. 2012;427(2):385-92.
125. Sharma K, Somavarapu S, Colombani A, Govind N, Taylor KM. Crosslinked chitosan nanoparticle formulations for delivery from pressurized metered dose inhalers. Eur J Pharm Biopharm. 2012;81(1):74-81.
126. Conti DS, Bharatwaj B, Brewer D, da Rocha SR. Propellant-based inhalers for the non-invasive delivery of genes via oral inhalation. J Control Release. 2012;157(3):406-17.
127. Tan Y, Yang Z, Peng X, Xin F, Xu Y, Feng M. A novel bottom-up process to produce nanoparticles containing protein and peptide for suspension in hydrofluoroalkane propellants. Int J Pharm. 2011;413(1-2):167-73.
128. Tam JM, Engstrom JD, Ferrer D, Williams RO, Johnston KP. Templated open flocs of anisotropic particles for pulmonary delivery with pressurized metered dose inhalers. J Pharm Sci. 2010;99(7): 3150-65.
129. Nyambura BK, Kellaway IW, Taylor KM. Insulin nanoparticles: stability and aerosolization from pressurized metered dose inhalers. Int J Pharm. 2009;375(1-2):114-22.
130. Johnson GA, Gutti VR, Loyalka SK, O’Beirne KA, Cochran SK, Dale HM. Albuterol metered dose inhaler performance under hyperbaric pressures. Undersea Hyperb Med. 2009;36(1):55-63.
131. Boyce N. New vaccines meant to block drug highs could help break a habit or keep one from starting. US News World Rep. 2003;134(14):54.
132. Saari SM, Vidgren MT, Turjanmaa VM, Koskinen MO, Nieminen MM. No impairment of peripheral deposition in novel asthmatics treated with an MDI corticosteroid with spacer. Respir Med. 2003;97(2):152-8.
133. Sommerville ML, Johnson CS, Cain JB, Rypacek F, Hickey AJ. Lecithin microemulsions in dimethyl ether and propane for the generation of pharmaceutical aerosols containing polar solutes. Pharm Dev Technol. 2002;7(3):273-88.
134. Kosoglou T, Hubbell J, Xuan F, Cutler DL, Meehan AG, Kantesaria B. Comparison of the systemic bioavailability of mometasone furoate after oral inhalation from a mometasone furoate/formoterol fumarate metered-dose inhaler versus a mometasone furoate dry-powder inhaler in patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2013;8:107-16.
135. Vehring R, Lechuga-Ballesteros D, Joshi V, Noga B, Dwivedi SK. Cosuspensions of microcrystals and engineered microparticles for uniform and efficient delivery of respiratory therapeutics from pressurized metered dose inhalers. Langmuir. 2012;28(42):15015-23.
136. Murnane D, Martin GP, Marriott C. Investigations into the formulation of metered dose inhalers of salmeterol xinafoate and fluticasone propionate microcrystals. Pharm Res. 2008;25(10):2283-91.
137. Lewis DA, Young PM, Buttini F, Church T, Colombo P, Forbes B. Towards the bioequivalence of pressurised metered dose inhalers 1: Design and characterisation of aerodynamically equivalent beclomethasone dipropionate inhalers with and without glycerol as a non-volatile excipient. Eur J Pharm Biopharm. 2014;86(1):31-7.
138. Saadat A, Zhu B, Haghi M, King G, Colombo G, Young PM. The formulation, chemical and physical characterisation of clarithromycin-based macrolide solution pressurised metered dose inhaler. J Pharm Pharmacol. 2013.
139. Sawatdee S, Hiranphan P, Laphanayos K, Srichana T. Evaluation of sildenafil pressurized metered dose inhalers as a vasodilator in umbilical blood vessels of chicken egg embryos. Eur J Pharm Biopharm. 2014;86(1):90-7.
140. Salvi S, Brashier B, Gothi D, Karkhanis V, Madas S, Gogtay J. Bronchodilator efficacy of tiotropiumformoterol via single pressurized meter dose inhaler (pMDI) versus tiotropium alone in COPD. Pulm Pharmacol Ther. 2014;27(1):90-5.
141. Tarara TE, Hartman MS, Gill H, Kennedy AA, Weers JG. Characterization of suspension-based metered dose inhaler formulations composed of spray-dried budesonide microcrystals dispersed in HFA- 134a. Pharm Res. 2004;21(9):1607-14.
142. Myrdal PB, Karlage KL, Stein SW, Brown BA, Haynes A. Optimized dose delivery of the peptide cyclosporine using hydrofluoroalkane-based metered dose inhalers. J Pharm Sci. 2004;93(4):1054-61.
143. McKeage K. Fluticasone propionate/formoterol fumarate: a review of its use in persistent asthma. Drugs. 2013;73(2):195-206.
144. Park CW, Li X, Vogt FG, Hayes D, Zwischenberger JB, Park ES. Advanced spray-dried design, physicochemical characterization, and aerosol dispersion performance of vancomycin and clarithromycin multifunctional controlled release particles for targeted respiratory delivery as dry powder inhalation aerosols. Int J Pharm. 2013;455(1-2):374-92.
145. Li H, Dong WF, Zhou JY, Xu XM, Li FQ. Triggering effect of N-acetylglucosamine on retarded drug release from a lectin-anchored chitosan nanoparticles-in-microparticles system. Int J Pharm. 2013;449(1-2):37-43.
146. Onoue S, Sato H, Kawabata Y, Mizumoto T, Hashimoto N, Yamada S. In vitro and in vivo characterization on amorphous solid dispersion of cyclosporine A for inhalation therapy. J Control Release. 2009;138(1):16-23.
147. Terzano C, Petroianni A, Parola D, Ricci A. Compressor/nebulizers differences in the nebulization of corticosteroids. Eur Rev Med Pharmacol Sci. 2007;11(4):225-37.
148. Collins N. Nebulizer therapy in cystic fibrosis: an overview. J R Soc Med. 2009;102:11-7.
149. Brocklebank D, Wright J, Cates C. Systematic review of clinical effectiveness of pressurised metered dose inhalers versus other hand held inhaler devices for delivering corticosteroids in asthma. BMJ. 2001;323(7318):896.
150. Rakesh Pahwa P, Manisha S, Mona P, Avneet Kaur L. Nebulizer therapy: a platform for pulmonary drug delivery. Der Pharmacia Sinica. 2012;3(6):630-6.
151. Finlay WH. The Mechanics of Inhaled Pharmaceutical Aerosols An Introduction Academic Press:London; 2001.
152. Hickey AJ. Pharmaceutical inhalation aerosol technology, Second Ed. Marcel Dekker, NY, USA. 2004.
153. Shen SC, Wang YJ, Chen YY. Design and fabrication of medical micro-nebulizer. Sensors and Actuators A: Physical. 2008;144(1):135-43.
154. O’Callaghan C, Barry PW. The science of nebulised drug delivery. Thorax. 1997;52 Suppl 2:S31-44.
155. Dhand R. Nebulizers that use a vibrating mesh or plate with multiple apertures to generate aerosol. Respir Care. 2002;47(12):1406-16.
156. Nikander K, Turpeinen M, Wollmer P. The conventional ultrasonic nebulizer proved inefficient in nebulizing a suspension. J Aerosol Med. 1999;12(2):47-53.
157. Leung K, Louca E, Coates AL. Comparison of breath-enhanced to breath-actuated nebulizers for rate, consistency, and efficiency. Chest. 2004;126(5):1619-27.
158. Anderson PJ. Delivery options and devices for aerosolized therapeutics. Chest. 2001;120(3 Suppl):89S-93S.
159. Kesser KC, Geller DE. New aerosol delivery devices for cystic fibrosis. Respir Care. 2009;54(6): 754-67.
160. Nasr M, Taha I, Hathout RM. Suitability of liposomal carriers for systemic delivery of risedronate using the pulmonary route. Drug Deliv. 2013;20(8):311-8.
161. Kamalaporn H, Leung K, Nagel M, Kittanakom S, Calvieri B, Reithmeier RA. Aerosolized liposomal amphotericin B: A potential prophylaxis of invasive pulmonary aspergillosis in immunocompromised patients. Pediatr Pulmonol. 2013.
162. Clancy JP, Dupont L, Konstan MW, Billings J, Fustik S, Goss CH. Phase II studies of nebulised Arikace in CF patients with Pseudomonas aeruginosa infection. Thorax. 2013;68(9):818-25.
163. de Jesus Valle MJ, Gonzalez JG, Lopez FG, Navarro AS. Pulmonary disposition of vancomycin nebulized as lipid vesicles in rats. J Antibiot (Tokyo). 2013;66(8):447-51.
164. Gaspar MM, Radomska A, Gobbo OL, Bakowsky U, Radomski MW, Ehrhardt C. Targeted delivery of transferrin-conjugated liposomes to an orthotopic model of lung cancer in nude rats. J Aerosol Med Pulm Drug Deliv. 2012;25(6):310-8.
165. Luo Y, Zhai X, Ma C, Sun P, Fu Z, Liu W. An inhalable beta(2)-adrenoceptor ligand-directed guanidinylated chitosan carrier for targeted delivery of siRNA to lung. J Control Release. 2012;162(1):28-36.
166. Videira M, Almeida AJ, Fabra A. Preclinical evaluation of a pulmonary delivered paclitaxel-loaded lipid nanocarrier antitumor effect. Nanomedicine. 2012;8(7):1208-15.
167. Sahib MN, Darwis Y, Peh KK, Abdulameer SA, Tan YT. Rehydrated sterically stabilized phospholipid nanomicelles of budesonide for nebulization: physicochemical characterization and in vitro, in vivo evaluations. Int J Nanomedicine. 2011;6:2351-66.
168. Beck-Broichsitter M, Kleimann P, Gessler T, Seeger W, Kissel T, Schmehl T. Nebulization performance of biodegradable sildenafil-loaded nanoparticles using the Aeroneb Pro: formu-lation aspects and nanoparticle stability to nebulization. Int J Pharm. 2012;422(1-2):398-408.
169. El-Gendy N, Pornputtapitak W, Berkland C. Nanoparticle agglomerates of fluticasone propionate in combination with albuterol sulfate as dry powder aerosols. Eur J Pharm Sci. 2011;44(4):522-33.
170. Tawfeek HM, Evans AR, Iftikhar A, Mohammed AR, Shabir A, Somavarapu S. Dry powder inhalation of macromolecules using novel PEG-co-polyester microparticle carriers. Int J Pharm. 2013;441(1- 2):611-9.
171. Yildiz A, John E, Ozsoy Y, Araman A, Birchall JC, Broadley KJ. Inhaled extended-release microparticles of heparin elicit improved pulmonary pharmacodynamics against antigen-mediated airway hyper-reactivity and inflammation. J Control Release. 2012;162(2):456-63.
172. Adi H, Young PM, Chan HK, Salama R, Traini D. Controlled release antibiotics for dry powder lung delivery. Drug Dev Ind Pharm. 2010;36(1):119-26.
173. Dellamary L, Smith DJ, Bloom A, Bot S, Guo GR, Deshmuk H. Rational design of solid aerosols for immunoglobulin delivery by modulation of aerodynamic and release characteristics. J Control Release. 2004;95(3):489-500.
174. Suarez S, O’Hara P, Kazantseva M, Newcomer CE, Hopfer R, McMurray DN. Airways delivery of rifampicin microparticles for the treatment of tuberculosis. J Antimicrob Chemother. 2001;48(3):431-4.
175. Vyas SP, Khatri K, Goyal AK. Functionalized nanocarrier(s) to image and target fungi infected immune cells. Med Mycol. 2009;47 (1):S362-8.
176. Liu J, Gong T, Fu H, Wang C, Wang X, Chen Q. Solid lipid nanoparticles for pulmonary delivery of insulin. Int J Pharm. 2008;356(1-2):333-44.
177. Pardeike J, Weber S, Haber T, Wagner J, Zarfl HP, Plank H. Development of an itraconazole-loaded nanostructured lipid carrier (NLC) formulation for pulmonary application. Int J Pharm. 2011;419(1- 2):329-38.
178. Thoren P, Wallin A, Whitehead PJ, Sandstrom T. The effect of different concentrations of lactose powder on the airway function of adult asthmatics. Respir Med. 2001;95(11):870-5.
179. Keating GM. Loxapine inhalation powder: a review of its use in the acute treatment of agitation in patients with bipolar disorder or schizophrenia. CNS Drugs. 2013;27(6):479-89.
180. Klier J, Fuchs S, May A, Schillinger U, Plank C, Winter G. A nebulized gelatin nanoparticle-based CpG formulation is effective in immunotherapy of allergic horses. Pharm Res. 2012;29(6):1650-7.
181. Hindi KM, Ditto AJ, Panzner MJ, Medvetz DA, Han DS, Hovis CE. The antimicrobial efficacy of sustained release silver-carbene complex-loaded L-tyrosine polyphosphate nanoparticles: characterization, in vitro and in vivo studies. Biomaterials. 2009;30(22):3771-9.
182. Geller DE. Comparing clinical features of the nebulizer, metered-dose inhaler, and dry powder inhaler. Respir Care. 2005;50(10):1313-21.
183. Fairshter RD. Evaluation of a metered-dose aerosol delivery system using partial flow-volume curves. Am Rev Respir Dis. 1987;135(3):741-3.
184. Thorsson L, Edsbacker S, Conradson TB. Lung deposition of budesonide from Turbuhaler is twice that from a pressurized metered-dose inhaler P-MDI. Eur Respir J. 1994;7(10):1839-44.
185. Selroos O, Backman R, Forsen KO, Lofroos AB, Niemisto M, Pietinalho A. Local side-effects during 4-year treatment with inhaled corticosteroids—a comparison between pressurized metered-dose inhalers and Turbuhaler. Allergy. 1994;49(10):888-90.
186. Olsson B. Aerosol particle generation from dry powder inhalers: can they equal pressurized metered dose inhalers? J Aerosol Med. 1995;8:S13-8.
187. Thorsson LTF, Korn S, Carlshaf A, Edsbacker S, Wouters EFM. Formation of fatty acid conjugates of budesonide in human lung tissue in vivo. Am J Respir Crit Care Med 1998;153:A404.
188. Shapiro G, Mendelson L, Kraemer MJ, Cruz-Rivera M, Walton-Bowen K, Smith JA. Efficacy and safety of budesonide inhalation suspension (Pulmicort Respules) in young children with inhaled steroiddependent, persistent asthma. J Allergy Clin Immunol. 1998;102(5):789-96.
189. Nikander K, Agertoft L, Pedersen S. Breath-synchronized nebulization diminishes the impact of patient- device interfaces (face mask or mouthpiece) on the inhaled mass of nebulized budesonide. J Asthma. 2000;37(5):451-9.
190. Brocklebank D, Ram F, Wright J, Barry P, Cates C, Davies L. Comparison of the effectiveness of inhaler devices in asthma and chronic obstructive airways disease: a systematic review of the literature. Health Technol Assess. 2001;5(26):1-149.
191. Dahlstrom K, Thorsson L, Larsson P, Nikander K. Systemic availability and lung deposition of budesonide via three different nebulizers in adults. Ann Allergy Asthma Immunol. 2003;90(2):226-32.
192. Vilarinho LC CMC, de Freitas Souza LS. Inalador dosimetrado com espaçador artesanal versus nebulizador no tratamento da crise de sibilância na criança. J Pediatr (Rio J). 2003(79):403-12.
193. Castro-Rodriguez JA, Rodrigo GJ. beta-agonists through metered-dose inhaler with valved holding chamber versus nebulizer for acute exacerbation of wheezing or asthma in children under 5 years of age: a systematic review with meta-analysis. J Pediatr. 2004;145(2):172-7.
194. Herberto J, Chong Neto DCCS, Daniele M, Marani Flávia Kuroda MO, Lúcia de N. Diferentes dispositivos inalatórios na crise aguda de asma:um estudo randomizado, duplo-cego e controlado com placebo. Jornal de Pediatria. 2005;81:298-304.
195. Vecellio L, De Gersem R, Le Guellec S, Reychler G, Pitance L, Le Pennec D. Deposition of aerosols delivered by nasal route with jet and mesh nebulizers. Int J Pharm. 2011;407(1-2):87-94.
196. Dolovich M., Ahrens RC, Hess DR, Anderson P, Dhand R, Rau JL. Device selection and outcomes of aerosol therapy: evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology. Chest. 2005;127(1):335-71.
197. Stegemann S, Kopp S, Borchard G, Shah VP, Senel S, Dubey R. Developing and advancing dry powder inhalation towards enhanced therapeutics. Eur J Pharm Sci. 2013;48(1-2):181-94.
198. Niven R. Prospects and challenges: inhalation delivery systems. Ther Deliv. 2013;4(5):519-22.
199. Fink JB. Delivery of inhaled drugs for infants and small children: a commentary on present and future needs. Clin Ther. 2012;34(11):S36-45.
200. Ari A, Fink JB. Guidelines for aerosol devices in infants, children and adults: which to choose, why and how to achieve effective aerosol therapy. Expert Rev Respir Med. 2011;5(4):561-72.
201. Garg T, Singh O, Arora S, Murthy R. Scaffold: a novel carrier for cell and drug delivery. Crit Rev Ther Drug Carrier Syst. 2012;29(1):1-63.
202. Fuglsang A. The US and EU regulatory landscapes for locally acting generic/hybrid inhalation products intended for treatment of asthma and COPD. J Aerosol Med Pulm Drug Deliv. 2012;25(4): 243-7.
203. Mitchell JP, Nichols SC. The 18th congress of the international society for aerosols in medicine. Ther Deliv. 2011;2(9):1115-9.